Wells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Key Points

• Wells Fargo raised its price target on Ultragenyx to $47 and maintained an overweight rating, implying roughly an 80% upside from the stock's recent price.
• Q1 miss: Ultragenyx reported EPS of ($1.84) vs. ($1.50) expected and revenue of $136M vs. $158M expected, and while it issued FY2026 revenue guidance of $730–$760M it left EPS guidance blank, creating mixed signals for investors.
• Mixed investor activity: Insiders sold about 111,178 shares (~$2.53M) last quarter even as institutional ownership climbed to roughly 97.7%, indicating simultaneous insider selling and continued institutional accumulation.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price increased by investment analysts at Wells Fargo & Company from $45.00 to $47.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price target indicates a potential upside of 80.28% from the company's current price.

A number of other research analysts also recently issued reports on the company. Barclays cut their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating on the stock in a report on Wednesday, April 29th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a report on Sunday. Weiss Ratings downgraded Ultragenyx Pharmaceutical from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, April 24th. Morgan Stanley lifted their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, April 16th. Finally, Wedbush cut their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.94.

Ultragenyx Pharmaceutical Stock Performance

RARE traded up $1.06 during trading on Wednesday, hitting $26.07. 550,771 shares of the stock were exchanged, compared to its average volume of 2,219,524. Ultragenyx Pharmaceutical has a 1 year low of $18.29 and a 1 year high of $42.37. The firm has a 50 day simple moving average of $22.55 and a 200 day simple moving average of $26.90. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -4.47 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.50) by ($0.34). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million during the quarter, compared to analysts' expectations of $158.38 million. During the same quarter in the prior year, the business posted ($1.57) earnings per share. The company's revenue was down 2.2% compared to the same quarter last year. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical will post -4.49 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Howard Horn sold 8,409 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the transaction, the chief financial officer directly owned 86,669 shares in the company, valued at $1,967,386.30. The trade was a 8.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $185,478.00. Following the transaction, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 111,178 shares of company stock worth $2,534,628 over the last quarter. Company insiders own 5.20% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company's stock valued at $8,414,000 after purchasing an additional 29,984 shares during the last quarter. Creative Planning purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $454,000. American Century Companies Inc. purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $366,000. M&T Bank Corp grew its stake in Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company's stock valued at $263,000 after purchasing an additional 1,192 shares during the last quarter. Finally, Amundi grew its stake in Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company's stock valued at $3,913,000 after purchasing an additional 93,189 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional investors increased positions in RARE, including large additions reported in recent filings — this signals continued institutional conviction that can support the stock. MarketBeat RARE Summary
• Neutral Sentiment: Company issued FY2026 revenue guidance of $730M–$760M (midpoint roughly in line with consensus), but left EPS guidance blank — the revenue range provides some visibility while the missing EPS target increases uncertainty. Press Release
• Neutral Sentiment: Analyst coverage remains mixed: Wedbush cut its price target slightly to $26 with a Neutral rating (small effect), while other shops have divergent views — overall consensus still skews toward moderate buy but with wide target dispersion. Benzinga PT Note
• Negative Sentiment: Q1 EPS missed materially: reported loss of ($1.84) vs. consensus ~($1.50), and revenue came in at $136M vs. ~$158M expected — the miss and year-over-year revenue decline are the primary drivers of today's downside pressure. Zacks Earnings Miss
• Negative Sentiment: Insider selling: CFO Howard Horn sold 4,683 shares in early May (disclosed SEC filing) — insider sales can be perceived negatively by the market even if not large relative to holdings. SEC Filing

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.